Comparative Pharmacology
Head-to-head clinical analysis: ARRANON versus AVOPEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARRANON versus AVOPEF.
ARRANON vs AVOPEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Purine nucleoside analog; after intracellular phosphorylation to ara-GTP, it incorporates into DNA, inhibits DNA synthesis, and induces apoptosis in T-cell progenitors.
Avopef is a synthetic peptide analog that acts as a selective antagonist of the nociceptin/orphanin FQ (N/OFQ) receptor (NOP), modulating pain pathways and stress responses. It also exhibits partial agonist activity at mu-opioid receptors, contributing to its analgesic and anxiolytic effects.
2600 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
Adults: 400 mg intravenously every 8 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life of nelarabine is approximately 30 minutes; the active metabolite ara-G has a terminal half-life of approximately 20-24 hours. Clinically, this supports daily dosing in cycles.
Terminal elimination half-life is 2.0-3.5 hours; prolonged to 6-12 hours in renal impairment.
Nelarabine is extensively metabolized to ara-G; elimination is primarily renal: ~27% as parent drug and 30-50% as ara-G in urine. Fecal excretion accounts for <5% of administered dose.
Renal: 70-80% unchanged; Biliary/Fecal: 15-20%; minor hepatic metabolism.
Category C
Category C
Antineoplastic
Antineoplastic